| Market Capitalization (Millions $) |
4,040 |
| Shares
Outstanding (Millions) |
187 |
| Employees |
503 |
| Revenues (TTM) (Millions $) |
4 |
| Net Income (TTM) (Millions $) |
1 |
| Cash Flow (TTM) (Millions $) |
246 |
| Capital Exp. (TTM) (Millions $) |
35 |
Business Description
Denali Therapeutics Inc is a biotechnology company that focuses on discovering and developing treatments for neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease.
The company was founded in 2015 by a group of leading scientists and drug developers from Genentech, including Ryan Watts, Alex Schuth, and Marc Tessier-Lavigne.
Denali's approach to drug development is based on the use of proprietary technologies such as the Transport Vehicle platform and the Neuroimmunology platform.
The Transport Vehicle platform is designed to allow large molecules such as antibodies to cross the blood-brain barrier, which is essential for treating neurodegenerative diseases.
The Neuroimmunology platform is focused on developing therapies that modulate the immune system's response to neurodegenerative diseases.
Currently, Denali has several drug candidates in its pipeline that are designed to address the underlying biology of neurodegenerative diseases.
One of the company's lead drug candidates is DNL151, an oral small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2), which is a genetically validated target for Parkinson's disease.
Denali also has a collaboration with Sanofi to develop potential treatments for multiple sclerosis and other neuroinflammatory disorders.
The company is headquartered in South San Francisco, California, and has over 400 employees, including scientists, researchers, and drug developers with extensive experience in the biotechnology industry.
Denali has received over $600 million in funding from leading investors such as Fidelity, Flagship Pioneering, and the Alaska Permanent Fund Corporation.
Overall, Denali is focused on developing breakthrough therapies that have the potential to improve the lives of patients with neurodegenerative diseases.
Company Address: 161 Oyster Point Blvd South San Francisco 94080 CA
Company Phone Number: 866-8547 Stock Exchange / Ticker: NASDAQ DNLI
|
2774.69 %